Molecular Trap for Removing Biotin Interference in Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Biotin interference in clinical diagnostic assays leads to instability and false results due to high biotin levels in patient samples, as free biotin competes with solid-phase-bound biotin for binding sites, affecting assay sensitivity and reliability.
Innovation Solution
A molecular hapten trap is introduced in the reagent formulation, which can be a soluble or solid cage that selectively captures and retains free biotin molecules, preventing them from interfering with the assay, using cyclodextrins or modified specific binding partners like traptavidin with slower binding kinetics to ensure biotin is locked and does not compete with biotinylated antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If biotin is used to coat solid support and bind to antibodies in immunoassays, then the binding strength and stability of the assay reagents is improved, but free biotin in patient samples competes for binding sites and causes false results
Solution Approach 1:
The patent introduces streptavidin as an intermediary component that binds to biotin with extremely high affinity (Kd in the attomolar range). By using streptavidin-coated solid support instead of direct biotin coating, the system mediates the interaction between biotinylated antibodies and the solid phase, reducing free biotin interference while maintaining strong binding.
Solution Approach 2:
The patent employs composite assay reagents where biotin is conjugated to antibodies (forming biotin-antibody conjugates) and streptavidin is coated on solid support. This composite approach combines the high affinity of biotin-streptavidin interaction with the functional capabilities of antibodies, creating a robust assay system resistant to free biotin interference.
2Stability of the object's composition
If covalent bonding is used to attach species to solid phase, then dissociation is eliminated and stability is improved, but in many cases this may be impossible or impractical
Solution Approach 1:
The patent changes the binding parameter from covalent bonding to non-covalent biotin-streptavidin interaction, which provides sufficiently stable binding (Kd in attomolar range) without requiring complex covalent attachment chemistry. This parameter change makes the assay manufacturing more feasible while maintaining stability.
Solution Approach 2:
By introducing streptavidin as an intermediary between the solid support and biotinylated antibodies, the patent achieves stable, reversible binding that eliminates the need for covalent crosslinking. The streptavidin-biotin interaction provides assay stability through its extremely low dissociation constant while simplifying the manufacturing process.
3Reliability
If free biotin is present in sample solutions, then it occupies binding sites and causes false results, but removing all biotin from the system eliminates the interference mechanism
Solution Approach 1:
The patent uses streptavidin as an intermediary that captures free biotin from sample solutions before it can compete with biotinylated antibodies for binding sites. The streptavidin-coated solid support acts as a biotin trap, sequestering free biotin and preventing it from interfering with the assay, thereby improving accuracy without eliminating biotin from the system.
Solution Approach 2:
The patent extracts free biotin from the sample solution by allowing it to bind to streptavidin on the solid support. This extraction removes the harmful free biotin from the solution phase while leaving biotinylated antibodies intact, eliminating the competition effect and improving assay reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The molecular trap effectively reduces biotin interference by selectively binding and retaining free biotin, maintaining assay sensitivity and reliability without affecting the assay signal, even in samples with high biotin levels, ensuring accurate detection of analytes.
Implementation Method 1
cyclodextrins or modified specific binding partners like traptavidin with slower binding kinetics to ensure biotin is locked
Implementation Method 2
modified specific binding partners like traptavidin with slower binding kinetics to ensure biotin is locked and does not compete with biotinylated antibodies
Data Source
AI summary
The present invention relates to methods and compositions to remove or reduce biotin interference from certain assays.